Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 9 results.
User Information
Export Records
  1. 1.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 2.   Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
  2. Ryan, Q. C.; Headlee, D.; Acharya, M.; Sparreboom, A.; Trepel, J. B.; Ye, J.; Figg, W. D.; Hwang, K.; Chung, E. J.; Murgo, A.; Melillo, G.; Elsayed, Y.; Monga, M.; Kalnitskiy, M.; Zwiebel, J.; Sausville, E. A.
  3. Journal of Clinical Oncology. 2005, JUN 10; 23(17): 3912-3922.
  1. 3.   Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following Ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE
  2. Pinczewski, J.; Zhao, J.; Malkevitch, N.; Patterson, L. J.; Aldrich, K.; Alvord, W. G.; Robert-Guroff, M.
  3. Viral Immunology. 2005, SPR; 18(1): 236-243.
  1. 4.   Enhanced tumor cell radiosensitivity and abrogation of G(2) and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  2. Bull, E. E. A.; Dote, H.; Brady, K. J.; Burgan, W. E.; Carter, D. J.; Cerra, M. A.; Oswald, K. A.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J.
  3. Clinical Cancer Research. 2004, DEC 1; 10(23): 8077-8084.
  1. 5.   Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes
  2. Penzak, S. R.; Shen, J. M.; Alfaro, R. M.; Remaley, A. T.; Natarajan, V.; Falloon, J.
  3. Therapeutic Drug Monitoring. 2004 26(3): 322-330.
  1. 6.   A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site
  2. Yoshimura, K.; Kato, R.; Kavlick, M. F.; Nguyen, A.; Maroun, V.; Maeda, K.; Hussain, K. A.; Ghosh, A. K.; Gulnik, S. V.; Erickson, J. W.; Mitsuya, H.
  3. Journal of Virology. 2002 76(3): 1349-1358.
  1. 7.   Rational approach to AIDS drug design through structural biology
  2. Wlodawer, A.
  3. Annual Review of Medicine. 2002 53: 595-614.
  1. 8.   HIV protease: Enzyme function and drug resistance
  2. Gulnik, S.; Erickson, J. W.; Xie, D.
  3. Vitamins and Hormones - Advances in Research and Applications, Vol 58. 2000 58: 213-256.
  1. 9.   Calculation of Relative Binding Free Energies of Peptidic Inhibitors to Hiv-1 Protease and Its I84v Mutant
  2. Tawa, G. J.; Topol, I. A.; Burt, S. K.; Erickson, J. W.
  3. Journal of the American Chemical Society. 1998 120(34): 8856-8863.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel